Owlstone Medical today announced it has partnered with Thermo Fisher Scientific, the world leader in serving science. The collaboration seeks to advance the application of non-invasive breath sampling to address the challenges of the early detection of disease and the precision medicine delivery of healthcare through the discovery and validation of novel biomarkers.
Under the agreement, both parties will work to integrate the Thermo Scientific™ Q Exactive™ GC Hybrid Quadrupole-Orbitrap™ Mass Spectrometer into Owlstone Medical’s Breath Biopsy platform. An initial project will seek to qualify the mass analyzer for the detection of new biomarkers via a validated discovery and routine analysis project. Upon successful completion, the technology will then become a standard part of Owlstone Medical’s biomarker discovery process, whereby metabolomic studies are conducted on breath samples for internal programs, or on behalf of pharmaceutical or academic clients, to discover novel biomarkers that could translate into research and clinical tests. The work will take place at Owlstone Medical’s Cambridge, UK, Breath Biopsy laboratory.
Further to the scientific and technical expertise, this collaboration will be supported by a joint marketing and customer support effort to ensure the global reach of the Breath Biopsy platform.